Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to E... (fit with EUSA's corporate strategy and t...)

HOME >> MEDICINE >> NEWS

Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma

Date:9/6/2007

fit with EUSA's corporate strategy and this transaction will ensure Innocoll is able to fully focus its own resources on the clinical development of Gentamicin Implant in the US where it is now entering phase 3, as well as on the global development of our other late stage products."

Bryan Morton, Chief Executive of EUSA Pharma said "Having learned of the excellent progress Innocoll has made in building a European sales and marketing presence it made strategic sense to partner with them to add it to our infrastructure and to work closely with them to bring the newer products to market. Innocoll's strength in development provides us with pipeline opportunities with outstanding potential".

About Gentamicin Surgical Implant

GENTAMICIN SURGICAL IMPLANT is a biodegradable leave-behind implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It was developed using Innocoll's proprietary collagen-based technology, CollaRx(R), and is indicated as an adjunct to systemic antibiotic therapy for the treatment and prevention of post-surgical acquired infection in both hard and soft tissues. There are approximately 60 prospective clinical trials and published case reports totalling over 7,500 patients documenting its safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular and neurosurgical procedures. One such clinical trial involving 2,000 patients undergoing a full median sternotomy during cardiac surgery demonstrated a 53% reduction in the incidence of sternal wound infection when the product was used as an adjunct to standard infection prophylaxis. GENTAMICIN SURGICAL IMPLANT has been approved in 49 countries in Europe, Latin America, Middle East, Africa and Asia and is marketed under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R) and CRONOCOL(R). An IND has been filed
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. GlaxoSmithKline Agrees To Settle Paxil Claims For $14 million
2. India and China Agrees to Promote Healthcare Jointly
3. China Agrees to Share Bird Flu Samples
4. Purdue Pharma Agrees to Pay $600 Million Fine for Misbranding Oxycontin
5. New spray gel heals surgical wounds
6. FDA approves surgical gel
7. Sleep apnoea linked to surgical risks
8. Lower surgical volume linked to higher death rate
9. Treatment Of Brain Aneurysms By A New Non-Surgical Approach
10. Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer
11. Indonesian boy with huge neck tumor was surgically removed

Post Your Comments:

Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to E...(fit with EUSA's corporate strategy and t...),Health